CD9 and ovarian cancer: Moreover, another study used an ExoProfile chip to analyze the circulating exosomes from the plasma of ovarian cancer patients, and revealed that the combinations of multiple markers, including EGFR, human EGFR 2 (HER2), CA125, folate receptor α (FRα), CD24, EpCAM, CD9, and CD63, in circulating exosomes potentially improved the efficacy for differentiating early- and late-stage ovarian cancer, yielding the best diagnostic AUC value.96